logo

Biomarin Pharmaceutical Inc. (BMRN)



Trade BMRN now with
  Date
  Headline
2/26/2020 4:06:46 PM BioMarin Q4 GAAP EPS $0.08 Vs Loss $0.03 Last Year
2/20/2020 4:10:18 PM BioMarin's Biologics License Application For Valoctocogene Roxaparvovec Accepted For Priority Review By FDA
2/3/2020 4:31:53 PM BioMarin CFO Dan Spiegelman Steps Down; Brian Mueller Named Acting CFO
1/22/2020 6:24:11 AM Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $158 Price Target
1/13/2020 8:31:56 AM BioMarin Plans To Begin Clinical Trial With BMN 307 Gene Therapy
12/23/2019 8:37:29 AM BioMarin Submits BLA To FDA For Valoctocogene Roxaparvovec To Treat Hemophilia A
12/23/2019 8:32:25 AM EMA Validates BioMarin's Marketing Authorization Application For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A
12/16/2019 8:20:38 AM BioMarin Reports Positive Final Results From Phase 3 Study Evaluating Vosoritide
11/14/2019 8:30:47 AM BioMarin Updates On Clinical Program For Vosoritide, Analog Of C-type Natriuretic Peptide
10/23/2019 4:08:50 PM BioMarin Q3 EPS $0.30 Vs. Loss $0.07 Year Ago
9/26/2019 8:39:19 AM BioMarin Submits Clinical Trial Application In U.K. For Investigational Gene Therapy For PKU
  
 
>